Los Angeles based leading biotechnology company Capricor Inc. today announced results of the preclinical studies of its cardiosphere-derived stem cells. The study shows possibility to protect the heart significantly better, when the cell is transplanted into a well-established mouse model of myocardial infarction (MI).

In this preclinical study, Dr. Ruckdeschel Smith and research collaboratorsat Johns Hopkins Medical Center as well as the University of Rome, compared transplantation of human CDCs, highly purified human cardiac stem cells,and human heart derived mesenchymal like progenitor cells into immunodeficient mice that had induced myocardial infarcts. Many questions remain to be answered on how various stem cells act when delivered into damaged heart.

ardiac degeneration after a heart attack leads to progressive loss of cardiac function ending in heart failure and death. This promising studywas conducted by Dr. Rachel Ruckdeschel Smith, Project Leader Regenerative Medicine, at Capricor, will be presented today at the American Heart Association 2008 Scientific Sessions.

Oliver Foellmer, President and CEO at Capricor said,

“This study confirms our previously published preclinical work that CDCshave a strong therapeutic effect when applied to animal models of heartattack. Preparationsfor a clinical trial testing CDCs in patients with recent heart attack arealready underway and we hope to file an IND with the FDA by the end of thisyear to investigate the beneficial impact that CDCs can have in patients.”

Source: International Business Times